Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 144.5% in March

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 60,400 shares, an increase of 144.5% from the March 15th total of 24,700 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 164,900 shares, the days-to-cover ratio is presently 0.4 days.

Astellas Pharma Stock Up 2.8 %

ALPMY stock opened at $9.13 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 0.39. The firm’s 50-day simple moving average is $9.62 and its 200 day simple moving average is $10.17. The stock has a market cap of $16.52 billion, a PE ratio of -41.50 and a beta of 0.31. Astellas Pharma has a fifty-two week low of $8.37 and a fifty-two week high of $13.14.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Tuesday, February 4th. The company reported $0.30 earnings per share for the quarter. Astellas Pharma had a positive return on equity of 13.69% and a negative net margin of 3.10%. As a group, sell-side analysts predict that Astellas Pharma will post 0.42 EPS for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.